Here are five takeaways:
1. The stock has a price target of $178.47 for March 30, which is 67 percent above $106.87 share price.
2. If the $178.47 price target is reached, the $39.82 billion company will be worth $26.68 billion more.
3. Out of 22 analysts covering Stryker, 18 rate it “buy,” two rate it “sell,” while nine rate it “hold.”
4. Since March 9, 2015, the stock has seen nine insider sales totaling $9.92 million in net activity.
5. Just yesterday, Stryker Director Ronda E. Stryker sold 12,000 shares of the company’s stock for a total of $1.25 million.
More articles on devices:
InVivo continues to see success with INSPIRE study—5 observations
Stryker gears up its challenge at first stop on PGA Tour: 3 notes
Amedica, Stryker, SI-BONE & & more: 12 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
